CompletedPhase 3

Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium

Egypt100 participantsStarted 2023-04-09

Plain-language summary

In population of intensive care unit (ICU), most studies compared atypical antipsychotics such as quetiapine with the traditional haloperidol in delirious patients of various forms and etiologies. The role of such agents in patients with hyperactive is not fully understood. This study compares the effectiveness of quetiapine with haloperidol in treating the hyperactive form of delirium in terms of their effects on morbidity, length of stay in the intensive care unit, and mortality in critically ill patients.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * All patients who are diagnosed with hyperactive form of delirium during their ICU stay using CAM-ICU tool (the confusion assessment method for the intensive care unit) Exclusion Criteria: * Suspected substance-induced delirium * Previous use of antipsychotics * Known allergy or intolerance to the study drugs * Pregnancy or breast feeding * Acute renal injury * Hepatic failure * Inability to tolerate oral drugs

What they're measuring

Response rate

Timeframe: Day 7

Trial details

NCT IDNCT05690698

SponsorAlexandria University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-07-15

View on ClinicalTrials.gov More Hyperactive Delirium trials